We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.46 | 0.17% | 274.00 | 273.99 | 274.12 | 274.45 | 269.645 | 270.63 | 561,314 | 17:12:05 |
From Apr 2021 to Apr 2024
By Stephen Nakrosis
Amgen Inc. said Wednesday the U.S. Food and Drug Administration approved Kyprolis in a combination regime to treat certain adult patients with relapsed or refractory multiple myeloma.
The company said the FDA expanded Kyprolis' prescribing information to include its use with Darzalex Faspro, or daratumumab and hyaluronidase-fihj, and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
Amgen said the expansion was supported by an ongoing Phase 2 trial evaluating Darzalex Faspro in combination with four standard-of-care treatment regimens in patients with multiple myeloma.
At 1:50 p.m. ET, Amgen shares were trading 2.4% higher at $203.59.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 01, 2021 14:12 ET (19:12 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
